Chad Landmon, JD, chair of Intellectual Property and FDA Practice at Axinn, Veltrop & Harkrider, provides a legal perspective on the implications of President Biden’s effort to improve the competitiveness of drug markets.
On July 9, 2021, President Biden signed a sweeping executive order intended to promote a more vibrant and competitive economy. The mandate contained provisions that affect the biosimilars market.
For insight into the significance of these initiatives, The Center for Biosimilars® spoke with Chad Landmon, JD, chair of the Intellectual Property and FDA Practice groups at Axinn, Veltrop & Harkrider, a law firm specializing in antitrust and intellectual property issues based in New York.
The executive order calls for the importation of drugs from Canada to help improve supply and lower prices in the United States. It also directs HHS to support the use of generic and biosimilar agents, and it increases pressure on the Federal Trade Commission to oppose “pay-for-delay” agreements that pharmaceutical companies sometimes employ to keep rival products off the market.
Among its provisions, the executive order also calls upon HHS to produce a comprehensive plan within 45 days to address high prescription drug prices and “price gouging.”
Landmon put these initiatives into context with background information and insight into the likely pharmaceutical industry impact and response.
He discusses the complications inherent in tackling pay-for-delay settlements as these, while not ideal, do carry the benefit of offering parties to a pharmaceutical dispute a way to set a timeline for bringing products to market, thereby avoiding costly litigation that could prevent lower-cost drugs from entering the market for substantially longer periods of time.
Landmon mentions California’s landmark anti–pay-for-delay legislation, signed into law in 2019, that prevents “anything of value” from being exchanged by pharmaceutical companies in exchange for a settlement. This law survived its first legal challenge last year when a federal judge denied a motion for relief by the Association for Accessible Medicines (AAM), a group representing generics and biosimilars manufacturers.
The AAM in a statement issued July 9, 2021, said it is willing to work with the Biden administration to accelerate adoption of lower-cost generics and biosimilars but wants to avoid extension of restrictions on drug dispute settlements such as California has imposed. “The White House should ensure that any new regulations do not restrict the ability to settle patent litigation with brand companies in a procompetitive manner,” the AAM said.
Drug imports from Canada were authorized during the Trump administration. For a recent Center for Biosimilars® article outlining the pros and cons of this initiative, click here.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.